Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Biodexa Pharmaceuticals ( (BDRX) ) just unveiled an announcement.
On August 18, 2025, Biodexa Pharmaceuticals announced the enrollment of the first two patients in its pivotal Phase 3 Serenta trial for eRapa, targeting familial adenomatous polyposis (FAP). This trial, conducted in collaboration with Emtora Biosciences and LumaBridge, marks a significant step as eRapa could become the first non-surgical treatment for FAP, addressing a $7.3 billion market. The trial aims to evaluate the safety and efficacy of eRapa, a proprietary formulation of rapamycin, in a double-blind placebo-controlled study involving 168 patients. The success of this trial could position Biodexa as a first mover in offering a therapeutic option for FAP, which currently lacks non-surgical treatments.
The most recent analyst rating on (BDRX) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Biodexa Pharmaceuticals stock, see the BDRX Stock Forecast page.
Spark’s Take on BDRX Stock
According to Spark, TipRanks’ AI Analyst, BDRX is a Neutral.
Biodexa Pharmaceuticals has a low overall stock score of 45, driven by significant financial challenges, bearish technical indicators, and a poor valuation. The lack of positive earnings guidance further adds to the uncertainty. The company must improve financial performance and operational efficiency to enhance investor confidence.
To see Spark’s full report on BDRX stock, click here.
More about Biodexa Pharmaceuticals
Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company focused on developing innovative products for diseases with unmet medical needs. The company’s lead programs include eRapa for Familial Adenomatous Polyposis (FAP) and Non-Muscle Invasive Bladder Cancer, tolimidone for type 1 diabetes, and MTX110 for rare brain cancers. Biodexa utilizes proprietary drug delivery technologies to enhance the bio-delivery and bio-distribution of medicines, with headquarters and R&D facilities in Cardiff, UK.
Average Trading Volume: 263,074
Technical Sentiment Signal: Sell
Current Market Cap: $470.7K
See more data about BDRX stock on TipRanks’ Stock Analysis page.